{"data":[{"accessionNo":"0002012383-26-003834","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":9834146,"percentOfClass":15.2,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Management, L.L.C.","reportingCik":null,"personType":"IA,OO","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"HC,IN","sharesOwned":6433119,"percentOfClass":9.99,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000405","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000093751-26-000527","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"PROTAGONIST THERAPEUTICS INC","ticker":"PTGX","cusip":"74366E102","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":3321554,"percentOfClass":5.2,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000093751-26-000283","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"PROTAGONIST THERAPEUTICS INC","ticker":"PTGX","cusip":"74366E102","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":3116804,"percentOfClass":4.9,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0002100119-26-000884","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics Inc","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":3250003,"percentOfClass":5.09,"filedAt":"2026-04-30","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0002100121-26-000589","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics Inc","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Portfolio Management","reportingCik":null,"personType":"IA","sharesOwned":3533015,"percentOfClass":5.53,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000102909-26-002110","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics Inc","ticker":"PTGX","cusip":"74366E102","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0001493215-26-000042","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-12-31","reportingPerson":"Roderick Wong","reportingCik":null,"personType":"HC,IN","sharesOwned":5059053,"percentOfClass":8.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0001493215-26-000042","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value","eventDate":"2025-12-31","reportingPerson":"RTW Investments, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5059053,"percentOfClass":8.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000902219-26-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":3171423,"percentOfClass":5.1,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000902219-26-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":3171423,"percentOfClass":5.1,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000902219-26-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":3171423,"percentOfClass":5.1,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":6248013,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":6126919,"percentOfClass":9.8,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4767564,"percentOfClass":7.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4767564,"percentOfClass":7.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":565080,"percentOfClass":0.9,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":290850,"percentOfClass":0.5,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":283062,"percentOfClass":0.5,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":121094,"percentOfClass":0.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":121094,"percentOfClass":0.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":53343,"percentOfClass":0.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":91421,"percentOfClass":0.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":39417,"percentOfClass":0.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":53343,"percentOfClass":0.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":36181,"percentOfClass":0.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Fried, Richard B","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Patel, Rajiv A.","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000908834-26-000054","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc.","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Seybold, William","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000102909-26-000253","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":5413690,"percentOfClass":8.65,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":2560916,"percentOfClass":4.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":2560916,"percentOfClass":4.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":2560916,"percentOfClass":4.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":2369107,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0001172661-25-004833","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001","eventDate":"2025-09-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":1715691,"percentOfClass":2.76,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0001172661-25-004833","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001","eventDate":"2025-09-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1715691,"percentOfClass":2.76,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0001172661-25-004833","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, par value $0.00001","eventDate":"2025-09-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":1715691,"percentOfClass":2.76,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":1323333,"percentOfClass":2.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1323333,"percentOfClass":2.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1045774,"percentOfClass":1.7,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1045774,"percentOfClass":1.7,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":140917,"percentOfClass":0.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0000921895-25-003110","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock, $0.00001 par value per share","eventDate":"2025-09-30","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":140917,"percentOfClass":0.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"},{"accessionNo":"0002012383-25-002687","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001377121","issuerName":"Protagonist Therapeutics, Inc","ticker":"PTGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":8575669,"percentOfClass":13.8,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx"}],"updatedAt":"2026-11-05T07:28:13.551Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/ptgx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}